Starpharma Holdings Limited (SPL.AX)

0.1350 +0.0100 (+8.00%) At close: 04:10PM AEST

Starpharma Holdings Limited

4-6 Southampton Crescent
Abbotsford, VIC 3067
Australia
61 3 8532 2700
https://starpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 45

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Justin Cahill	CFO & Company Secretary	127.7k	N/A	N/A
Ms. Cheryl Maley B.Sc., M.B.A.	CEO, MD & Director	N/A	N/A	1969

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.

Corporate governance

Starpharma Holdings Limited’s ISS governance QualityScore as of 1 April 2024 is 3. The pillar scores are Audit: 6; Board: 4; Shareholder rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.